Showing results (51-60 of 75) with videos related to

Sort By:
Pageof 8
The Lancet. Oncology|October 26, 2018
Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trialKohei Shitara, Toshihiko Doi, Mikhail Dvorkin, et al.
The Oncologist|May 30, 2024
Health-related quality-of-life analysis from KEYNOTE-590: pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancerWasat Mansoor, Seongjung Joo, Josephine M Norquist, et al.
BMC Cancer|June 12, 2022
The LEGACy study: a European and Latin American consortium to identify risk factors and molecular phenotypes in gastric cancer to improve prevention strategies and personalized clinical decision making globallyTessa Suzanne van Schooten, Sarah Derks, Elena Jiménez-Martí, et al.
British Journal of Cancer|November 6, 2022
A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancerGiuseppe Curigliano, Geoffrey I Shapiro, Rebecca S Kristeleit, et al.
BMC Cancer|September 14, 2017
A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancerKerry Lynn Reynolds, Philippe L Bedard, Se-Hoon Lee, et al.
The Oncologist|March 20, 2023
Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study PlatformAndrew H Ko, Kyu-Pyo Kim, Jens T Siveke, et al.
BMC Cancer|November 3, 2023
Ibrutinib combination therapy for advanced gastrointestinal and genitourinary tumours: results from a phase 1b/2 studyDo-Youn Oh, Maria Alsina Maqueda, David I Quinn, et al.
Critical Reviews in Oncology/Hematology|February 21, 2018
ECCO essential requirements for quality cancer care: Oesophageal and gastric cancerWilliam Allum, Florian Lordick, Maria Alsina, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 24, 2019
Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 CriteriaIgnacio Matos, Juan Martin-Liberal, Alonso García-Ruiz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2013
Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumabCarlos Gomez-Martin, Jose Carlos Plaza, Roberto Pazo-Cid, et al.
Pageof 8